uniQure Announces Publications of Preclinical Data for AMT-130 in Huntington's Disease Showing Safety of Administration in NHPs and Widespread Long-Term HTT-Lowering in the BrainGlobeNewsWire • 04/08/21
uniQure Announces Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's DiseaseGlobeNewsWire • 04/05/21
uniQure Stock Is Higher After Investigators Conclude Its Gene Therapy Treatment Was Unlikely to Have Caused a Patient's CancerBarrons • 03/29/21
Uniqure Stock Pops After Gene Therapy Acquitted In Cancer DiagnosisInvestors Business Daily • 03/29/21
Uniqure's Hemophilia B Gene Therapy Unlikely To Be Cause Of Liver Cancer Reported In One PatientBenzinga • 03/29/21
uniQure Announces Findings from Reported Case of Hepatocellular Carcinoma (HCC) in Hemophilia B Gene Therapy ProgramGlobeNewsWire • 03/29/21
uniQure Announces 2020 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 03/01/21
UniQure (QURE) to Report Q4 Results: Wall Street Expects Earnings GrowthZacks Investment Research • 02/22/21
UniQure's stock rallies 7% on positive safety data for Huntington's disease treatmentMarket Watch • 02/08/21
uniQure Announces Positive Recommendation from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's DiseaseGlobeNewsWire • 02/08/21
Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure DivesInvestors Business Daily • 12/21/20
UniQure Plunges As FDA Slaps Clinical Hold On Hemophilia B Gene Therapy Study On Possible Liver Cancer LinkBenzinga • 12/21/20
uniQure Announces Two-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia BGlobeNewsWire • 12/07/20